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Opinion statement
Purpose of review With established immunosuppressant treatment regimens for anti-
neutrophil cytoplasm antibody-associated vasculitides (AAV), prognosis has significantly
improved. The mainstay of treatment still comprises high-dose corticosteroids and cyclo-
phosphamide for severe forms, although rituximab is being increasingly utilised instead of
cyclophosphamide as induction therapy. AAV patients experience an excess of infections,
malignancies and cardiovascular events as compared to the general population, which is a
combination of the systemic inflammatory process associated with vasculitis and the
adverse events from treatment.
Recent findings Successful therapy should focus on suppressing disease activity and
minimising treatment-related toxicity. Infection is the largest contributor to morbidity
and mortality in the first year of treatment, and annual pneumococcal and influenza
vaccinations, Pneumocystis jiroveci prophylaxis and tuberculosis (TB) and Hepatitis B virus
screening are advised. Patients on high-dose corticosteroid treatment should have regular
blood sugar monitoring, a FRAX assessment with vitamin D and calcium supplementation,
consideration of prophylaxis for gastric ulcers and a cardiovascular risk assessment.
Patients who are treated with cyclophosphamide could also receive MESNA to reduce the
risk of chemical cystitis. Cyclophosphamide, methotrexate and azathioprine all require
blood monitoring schedules due to the risk of bone marrow suppression, liver and renal
toxicity. Hypogammaglobulinaemia is a recognised risk of rituximab treatment. Patients
of reproductive age need to be counselled on the infertility risks with cyclophosphamide
and the teratogenicity associated with it, methotrexate and mycophenolate mofetil.
Summary A greater focus on identifying clinical and biological markers that will help
identify those patients at greatest risk of relapse, e.g. GPA and PR3-ANCA specificity, from
those patients at greatest risk of toxicity, e.g. increasing age and declining GFR, is
required to allow treatment to be tailored accordingly.
Introduction
The introduction of effective immunosuppressive thera-
py to treat granulomatosis with polyangiitis (GPA) and
microscopic polyangiitis, commonly grouped as anti-
neutrophil cytoplasm antibody-associated vasculitis
(AAV), has significantly changed prognosis. Untreated,
these conditions are almost universally fatal [1]. Follow-
ing the introduction of cyclophosphamide and
corticosteroid-based immunosuppressive regimens, sur-
vival rates approach 80% at 5 years [2], with infection,
cardiovascular disease and malignancy being the
commonest causes of death. Although improved, this
remains 2.6 times worse than an age and sex-matched
healthy population, with death predicted by age, glo-
merular filtration rate G 15 ml/min and higher disease
severity [2]. The greatest risk to patients with AAV is in
the first year of diagnosis and most commonly from the
adverse events associated with treatment rather than
active vasculitis [3]. A study of patients with GPA using
primary care data noted a 9-fold increase in mortality
compared with a control population in the first year
following diagnosis [4].
The improvement in survival has changed our per-
ception of vasculitides from acutely fatal diseases to
chronic conditions with a relapsing remitting nature
and high morbidity due to disease damage and the side
effects associated with treatment. There is a complex
relationship between the severity of vasculitis and the
risk of developing adverse events, with the estimated
glomerular filtration rate (eGFR) being consistently
found to be the greatest overall predictor. This is prob-
ably due to reduced excretion of active drugmetabolites,
as well as the general immunosuppressive effect of kid-
ney failure. Damage due to disease and treatment is
common and increases with time. In a long-term fol-
low-up study of patients recruited to four European AAV
trials, over 30% of patients reported greater than 5 dam-
age items at long-term follow-up using the Vasculitis
Damage Index (VDI) [5]. Patients with damage are also
at increased risk of death [6].
The insight we now have intomorbidity andmortality
in AAV highlights the need for a change in our treatment
approach to maximise efficacy and minimise toxicity.
Treatment
Treatment overview
The treatment of AAV is usually divided into two phases comprised of
induction of remission and maintenance of remission. The latest 2015
recommendations from European league against rheumatism, European
Renal Association and European Vasculitis Study (EULAR/ERA-EDTA) state
that with organ or life-threatening disease, treatment typically involves
pulsed cyclophosphamide or rituximab with high-dose corticosteroids (e.g.
1 mg/kg/day oral prednisolone, or intravenous methylprednisolone 0.5–
1.0 g/day for 3 days) [7]. For those patients with pulmonary haemorrhage
or rapidly progressive renal failure, plasma exchange should be considered.
Patients with non-organ threatening disease may be successfully treated
with a less toxic induction regimen of either methotrexate or mycopheno-
late mofetil alongside corticosteroids [7].
Maintenance therapy then consists of azathioprine, methotrexate or rituxi-
mab with corticosteroid tapering. There is great variation in the approach to
corticosteroid tapering, but a target of between 7.5 and 10 mg of prednisolone
(or equivalent) after 3 months of treatment is considered appropriate [7]. The
duration of maintenance therapy is less clear.
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Treatment must take into account quality of life (QOL) for patients with
AAV. QOL among AAV patients is frequently poor and determined by multiple
clinical and bio-psychosocial factors, of which fatigue appears to be of principal
importance [8]. Whilst optimising disease control can improve QOL, non-
pharmacological interventions targeting bio-psychosocial determinants may be
more beneficial. AAV therapy must focus on person-centred outcomes such as
QOL and ascertainingwhat a patient’s priorities are for themanagement of their
chronic disease.
Infection
Infection is a considerable cause ofmorbidity andmortality associated with AAV,
and the immunosuppressive agents used to treat vasculitis are an undoubtable
contributor to this. Overall, approximately 30% of patients will suffer from a
serious infection requiring hospital admission, with respiratory infections being
most common [9, 10]. The greatest risk to patients is in the first year, reflecting the
intensity of immunosuppression [3, 11]. Higher doses of corticosteroids are also
associated with infectious risk [9, 12, 13]. During infection, consideration should
be given to pausing cytotoxic therapies especially if severe.
Advancing age and declining GFR are associated with increased risk of
infection and mortality [3, 14, 15]. Immune dysfunction induced by AAV
therapy predisposes to infection through neutropenia, reduced B and T cell
numbers, aberrant cell function and reduced immunoglobulin levels [16].
Close monitoring of the peripheral blood count is recommended during AAV
therapy as all cytotoxic therapies are associated with bone marrow suppression
[3] (Table 1). Granulocyte colony-stimulating factor (G-CSF), commonly used
in oncology for patients with neutropenia following chemotherapy, has been
shown to be effective at reducing the duration of neutropenia in AAV and may
be used safely, if necessary, without increasing risk of relapse [17].
Bacterial infections are common in AAV patients, accounting for up to 62% of
major infections, in particular those causing pneumonia. Opportunistic
Pneumocystis jiroveci pneumonia (PJP) has an incidence of 0.85–12% with in-
creased mortality in AAV [18–20]. Although PJP is generally associated with a
defect in T cell-mediated immunity, B cells have also been shown to play an
important role in the defence against pneumocystis [21]. Prophylaxis with co-
trimoxazole (800/160mg on alternate days or 400/80mg daily) is recommended
for all patients undergoing cyclophosphamide or rituximab treatment [7].
GPA patients have higher Staphylococcus aureus colonisation of the upper
respiratory tract which has been associated with a higher rate of relapse [22–24].
In patients with nasal disease, treatment with topical antibiotics such as
mupirocin may be considered in the presence of chronic carriage of nasal
Staphylococcus aureus [7, 25].
Vaccination should be used to reduce the risk of respiratory infections. The
EULAR guidelines conclude that pneumococcal and seasonal influenza vacci-
nations are safe and effective and recommended for all patients with autoim-
mune inflammatory disease [11, 26]. Not all patients with AAV will have an
adequate response to vaccination due to immune dysfunction [3]. Poor im-
munologic function, including low IgG, B cell counts and CD4 T cell counts,
predict vaccine response and mortality [16]. Current EULAR recommendations
are to avoid vaccination during B cell depletion therapy, e.g. with rituximab, as
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this has been consistently shown to impair humoral responses to influenza,
pneumococcal and tetanus toxoid immunisations in patients with rheumatoid
arthritis [27, 28]. Live attenuated vaccinations should be avoided in immuno-
compromised patients as live vaccines can, in some situations, cause severe or
fatal infections due to extensive replication of the vaccine strain.
Mycobacterium tuberculosis infection has only rarely been reported in AAV
patients, but can be fatal; the majority of cases show reactivation of latent TB.
Current British Society of Rheumatology (BSR) and BritishHealth Professionals
in Rheumatology (BHPR) guidance recommends that all AAV patients require a
thorough history, clinical examination and chest X-ray to screen for TB before
commencing immunosuppressive therapy [25, 29]. TB prophylaxis is then
indicated if latent TB is detected [25].
Viral infections are common, responsible for 35.8% of all major infec-
tious episodes seen in one long-term analysis [9]. The occurrence of herpes
zoster virus (HZV), shingles, occurs more often in AAV patients than a
healthy population, with a frequency of 4.5 episodes of HZV/100 patient
years compared to 0.40/100 patient years in the general population [12,
30]. Prophylaxis against varicella zoster virus (VZV) is not routinely rec-
ommended due to the non-life-threatening nature of VZV alongside the
high risk of drug interactions and adverse events especially with renal
dysfunction [25]. The varicella vaccine is a live attenuated vaccine and
guidance for its use in immunosuppressed patients is mixed; if possible the
vaccine should be administered prior to starting immunosuppression. Re-
cently, a vaccine using recombinant VZV glycoprotein E has been shown to
have benefit in reducing the risk of herpes zoster and post-herpetic
Table 1. Treatment-specific blood monitoring schedules for ANCA vasculitis therapy (compiled from [29] and [55])
Drug Laboratory
monitoring
Frequency
Methotrexate FBC
LFTs, albumin
Creatinine and
eGFR
• Pre-treatment, baseline levels
• Every 2 weeks until on stable dose for 6 weeks
• Then once on a stable dose, monthly for 3 months
• After this at least every 12 weeks
• Dose increases should be monitored with FBC every 2 weeks until on stable dose
for 6 weeks, then return to normal schedule
• More frequent monitoring is required for patients at high risk for toxicity, i.e.
chronic kidney disease and other risk factors for liver disease
Azathioprine FBC
LFTs, albumin
Creatinine and
eGFR
*as above
Pulsed
cyclophosphamide
FBC
LFTs, albumin
Creatinine and
eGFR
• Pre-treatment baseline levels
• 7–10 days after first pulse
• Then prior to giving next pulse
• Unless dose changed, only require FBC monitoring prior to subsequent pulses
• If WBC prior to pulse is G 4 × 109/L and neutrophils G 2 × 109/L, postpone
treatment until above these counts and reduce next dose by 25%
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neuralgia in those over 70 and would be suitable for use in immunosup-
pressed populations when available [31].
Latent infection with cytomegalovirus (CMV) is less frequent in AAV pa-
tients than in solid-organ transplantation, accounting for only 7.5% of major
infectious episodes seen in long-term follow-up studies [9]. Whilst CMV poly-
merase chain reaction (PCR) monitoring and prophylaxis with valganciclovir
are established in solid-organ transplantation follow-up, these are not routinely
recommended in AAV [25].
Hepatitis B virus (HBV) reactivation occurs early in patients receiving ritux-
imab or cyclophosphamide therapy for immune-mediated inflammatory dis-
orders and is an important cause of hepatic failure [32]. All patients receiving
significant immunosuppression should be screened for HBV infection and to
perform HBV vaccination in patients with a negative result. Guidelines recom-
mend that hepatitis B surface antigen (HBsAg)-positive patients receive pre-
emptive antiviral therapy before starting therapy and that hepatitis B core
antibody (HBcAb)-positive patients should be considered for preemptive anti-
viral therapy if rituximab or cyclophosphamide are given [32, 33].
Invasive fungal infections are rare in AAV patients, so systemic anti-fungal
prophylaxis is not indicated. A Cochrane review noted that oral nystatin was no
better than placebo at preventing candida infections in immunosuppressed
patients. Consideration should be given to using fluconazole if prophylaxis or
treatment is required [34].
Progressive multifocal leucoencephalopathy (PML) is a rare demyelinating
infection of the central nervous system caused by John Cunningham virus
which can result in irreversible neurological damage and death. Cases of PML
have been reported in patients receiving cyclophosphamide and/or rituximab
[35]. Clinicians must consider PML in their differentials for neurological pre-
sentations in patients who are heavily immunosuppressed as earlier diagnosis
and restorations of immune function with withdrawal of immunosuppression
may improve outcomes [36].
Corticosteroids
Other adverse events are treatment specific. The extensive side effect profile
associated with corticosteroids is well established. Data collected from four
European trials showed that of AAV patients treated with corticosteroids within
the first year, 8.2% developed new onset diabetes, 50% of which occurred
within 1.7 months [3]. 29% of patients gained over 10 kg weight, 2.6%
developed peptic ulceration, 2.5% had fractures, 2% developed cataracts and
0.4% developed avascular necrosis [3]. The adverse effects from corticosteroids
are even more pronounced with increasing length of exposure. At long-term
follow-up (median 5 years) of 270 patients, 41% had hypertension, 38%
osteoporosis, 28% diabetes mellitus and 25% had developed cataracts [5].
Corticosteroid administration modulates carbohydrate metabolism partic-
ularly in adipose tissue as well as inducing insulin resistance, with impaired
glucose uptake stimulating gluconeogenesis [37]. Risk factors for diabetes
include previous corticosteroid-induced hyperglycaemia, pre-diabetes, obesity
or a family history of diabetes [37]. Capillary blood glucose should be closely
monitoredwhilst patients are on corticosteroids; if persistently over 12mmol/L,
treatment should be commenced.
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Osteoporosis is a concern in patients with AAV. Corticosteroids promote
osteoporosis through direct cellular effects stimulating a positive effect on
osteoclasts, leading to increased bone resorption, and a negative effect on
osteoblasts and osteocytes, causing reduced bone formation and reduced repair
of micro-damaged bone. AAV alone is also associated with reduced BMD,
although the mechanisms for this are not yet fully understood. In a cross-
sectional study involving 99 patients with AAV treated with corticosteroids and
cyclophosphamide, 78% of patients were found to have abnormal dual-energy
X-ray absorptiometry (DEXA) measurements in one of three sites (the lumbar
spine, proximal femur or radius); 21% of these patients had osteoporosis and
57% osteopenia [38]. Cumulative dosage of corticosteroid therapy was in-
versely related to Z-score; significant correlations were also seen between bone
mineral density (BMD) and renal function [38]. Current UK guidelines devel-
oped by the National Osteoporosis Guideline Group (NOGG) advise assess-
ment with FRAX® tool for all patients identified to be at risk of osteoporosis, to
help guide further investigations and treatment.
Both the American College of Rheumatology and NOGG guidance sug-
gests lifestyle advice should be given to all patients on commencement of
long-term corticosteroid therapy including smoking cessation, alcohol
limitation and regular exercise [39, 40]. Oral calcium and vitamin D sup-
plementation is recommended for all patients undergoing long-term corti-
costeroid therapy [29, 41]. A Cochrane meta-analysis of 274 patients on
corticosteroids taking calcium and vitamin D compared to placebo showed
a clinically and statistically significant increase in bone mineral density of
2.6% at 2 years [41]. Bone-protective treatment with oral bisphosphonates
should be started at the onset of corticosteroid therapy in individuals at
moderate or high risk of fracture [40]. Bisphosphonate therapy is contra-
indicated in patients with significant renal impairment (GFR G 30 ml/min).
Special consideration should be given to women of child-bearing potential
due to the risk of foetal harm [40].
There is evidence that there is an increased risk of cardiovascular disease
(CVD) in AAV patients [42]. Outcomes from the EUVAS trials showed that 14%
of AAV patients have a cardiovascular event within 5 years of diagnosis; risk
factors included MPO-ANCA positivity, increasing age and diastolic hyperten-
sion [43]. Whilst the mechanisms behind this association are not fully under-
stood, it is believed that inflammation accelerates atherosclerosis through
endothelial dysfunction [44]. Corticosteroid use may also increase cardiovas-
cular risk [45]. Corticosteroids are known to cause multiple metabolic side
effects including hypertension, hyperlipidaemia, weight gain and diabetes
which are all significant cardiovascular risk factors. Due to this established
increased risk of CVD in AAV patients, EULAR guidelines advise annual review
of traditional Framingham risk factors [7].
It is also advisable to consider prophylactic gastric protection for AAV
patients receiving a prolonged course of high-dose corticosteroids due to the
risk of mucosal irritation.
Whilst it is appreciated that steroids are associated with significant toxicity,
there is limited data available on the most appropriate duration of treatment or
dose. Early withdrawal has been associated with increased disease relapse [46].
Data from EUVAS trials demonstrated that approximately half (47.8%) of the
patients were on glucocorticoids beyond 2 years, with a mean duration of
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corticosteroid use of 40.4 months [5]. New studies are addressing the need and
dose of corticosteroids required to treat AAV. PEXIVAS (plasma exchange and
glucocorticoid dosing in the treatment of ANCA-associated vasculitis) addresses
initial corticosteroid dosage (http://clinicaltrials.gov/ct2/ show/NCT00987389).
The CLEAR (C5aR inhibitor on leukocytes exploratory ANCA-associated renal
vasculitis) study has just been published investigating a new C5aR inhibitor
avacopan as a replacement for high-dose glucocorticoids in treating newly diag-
nosed or relapsing AAV [47].
Cyclophosphamide
Cyclophosphamide is an alkylating agent, which is metabolised by cytochrome
P450 to acrolein and phosphoramidemustard. Phosphoramide mustard forms
covalent bonds with DNA inducing lymphopenia, particularly of B cells and
suppressing humoral responses. Cyclophosphamide metabolites are primarily
excreted in the urine unchanged, resulting in increased systemic drug exposure
in those with renal dysfunction. Dosing should be reduced for both age and
renal function to reduce the risk of bone marrow suppression (Table 2). These
metabolites are toxic to the bladder and can cause haemorrhagic cystitis and
bladder cancer [48, 49]. Consideration should be given to the use of oral
or intravenous 2-mercaptoethanesulfonate sodium (MESNA) for patients
receiving intravenous cyclophosphamide alongside adequate hydration
[7, 29]. MESNA binds to acrolein, a toxic metabolite of cyclophospha-
mide, rendering it non-toxic [49]. Current guidelines recommend routine
surveillance with urinalysis; this should be continued indefinitely fol-
lowing initiation of any cyclophosphamide therapy. If non-glomerular
haematuria is confirmed on urine microscopy, a urology referral should
be sought [7].
The cumulative dose of cyclophosphamide, with a threshold of 36 g, in-
creases the risk of malignancy [50]. The overall incidence of cancer in AAV
patients was previously reported as being up to two times higher than that of
general population, with bladder cancer, non-melanoma skin cancer (NMSC),
leukaemia and lymphoma being the most common malignancies [12, 14].
Recent studies suggest that with reduction in cyclophosphamide dosing, only
NMSC is increased [51]. AAV patients should be educated on the risk of skin
malignancy and should be strongly encouraged to attend the national cancer
screening programs.
Table 2. Dose modification of pulsed cyclophosphamide as used in the CYCLOPS trial and stated in the EULAR ANCA
vasculitis guidelines [79]
Pulsed dose cyclophosphamide reductions for age and renal function
Age (years) Creatinine (μmol/L)
G 300 300–500
G 60 15 mg/kg/pulse 12.5 mg/kg/pulse
60–70 12 mg/kg/pulse 10 mg/kg/pulse
9 70 10 mg/kg/pulse 7.5 mg/kg/pulse
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Methotrexate
Methotrexate is an anti-folate drug with anti-proliferative and anti-inflammatory
effects, due to the inhibition of several key enzymes involved in folate,methionine,
adenosine and de novo nucleotide synthesis pathways [52]. Side effects are com-
monwith 10–37%of patients discontinuing treatment due to toxicity. GI toxicity is
frequent although usually mild, associated with diarrhoea, nausea and vomiting;
30% of patients will develop abnormal LFTs although this maybe transient.
Regular monitoring of liver function tests is recommended especially in those with
other risk factors for liver disease [53] (Table 1). Patients are advised to limit
alcohol intake whilst taking methotrexate to reduce the risk of liver toxicity.
Interstitial pneumonitis, although rare, remains a concern with methotrex-
ate use; a low threshold for investigations is required for patients on metho-
trexate presenting with new or increasing dyspnoea or a dry cough. If detected
early and methotrexate is discontinued, most patients recover without pro-
gression to lung fibrosis [53]. Renal failure from low-dose methotrexate is rare;
however, as it is primarily excreted by the kidneys, it is contraindicated in severe
renal impairment and should be used with caution if creatinine 9 150 μmol/L.
All patients should be co-prescribed folic acid supplementation at aminimal
dose of 5 mg once weekly, as adverse effects from methotrexate are thought to
be mediated by folate antagonism [54, 55].
Azathioprine
Azathioprine is a prodrug of mercaptopurine, which is subsequently
metabolised by several pathways, one of which involves the enzyme thiopurine
methyltransferase (TPMT). Azathioprine may cause a toxic reaction, which
results in hepatotoxicity and myelosuppression and is related to variation in
TPMT levels. Up to 14% of the population is known to have reduced levels of
this enzyme as a result of genetic mutations [56]. The positive predictive value
of measuring TPMT levels is widely debated, but British Society of Rheumatol-
ogy guidelines state that patients should have baseline TPMT status assessed
[55]. Allopurinol, a xanthine oxidase inhibitor, an enzyme involved in
metabolising 6-mercaptopurine, should not be used with azathioprine due to
the high risk of bone marrow suppression.
Rituximab
The safety of rituximab has become a topic of great interest with its increasing
use in both remission induction and maintenance therapy in AAV. Rituximab
was first used successfully to treat rheumatological disease without significant
rates of infection at long-term follow-up, so its promise in reducing the toxicity
from cumulative doses of cyclophosphamide and ongoing maintenance ther-
apy was particularly appealing [57, 58]. Whilst its efficacy has been demon-
strated, its side effect profile remains in question as the trials demonstrating
efficacy failed to show any difference in adverse events, such as infection, in
patients with AAV [59, 60].
The advantages of rituximab in reducing infections rates as demonstrated in
patients with rheumatoid arthritis, may not havematerialisedwithin these trials
as the follow-up periods may not have been long enough to have incorporated
the benefit from reduced cumulative cyclophosphamide exposure and
prolonged maintenance therapy [60].
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Hypoimmunoglobulinaemia is associated with the use of cyclophospha-
mide and rituximab [61]. A recent retrospective study of 243 patients with
multi-system disease treated with rituximab demonstrated that 56% had IgG
hypoimmunoglobulinaemia during follow-up; although in 50%, this was
transient. Only 4.2% of these patients required serum IgG replacement for
infection [62]. EULAR guidelines state that surveying patients with AAV is
warranted post cyclophosphamide and rituximab treatment for serum immu-
noglobulin concentrations and persisting hypoimmunoglobulinaemia [7].
Late-onset neutropenia (LON), defined as an absolute neutrophil count
(ANC) G 1.5 × 109/L at least 4 weeks after the last infusion, has been observed
in patients with rheumatological disease, including AAV treated with rituximab
[63]. A recent study involving 59 patients with AAV treated with rituximab
demonstrates that 7 patients (11.9%) developed LON after a median time of
86 days (range 56–168 days) since their latest rituximab treatment [64]. LON is
idiosyncratic in its development; it may occur after both single and repeated
rituximab courses and does not recur after subsequent doses of rituximab. No
predisposing factors for LON have been identified.
Fertility and pregnancy
Disease activity and its therapy are threats to the fertility of patients with
vasculitis. The cumulative dose of cyclophosphamide and increasing age at
initiation of treatment both increase the risk of primary ovarian failure [65, 66].
Data from a lupus trial suggests that a total cyclophosphamide exposure of 14–
20 g causes infertility in 9 50% of women aged over 32 years, with a lower risk
in younger women [67]. The long-term effects of rituximab on fertility and
teratogenicity during pregnancy have not been studied, but no concerns have
been reported suggesting rituximab should be used for young patients with AAV
wishing to preserve fertility [7].
Cyclophosphamide, methotrexate and mycophenolate mofetil are terato-
genic. Patients taking these agents should be counselled on this and advised to
use effective contraception for the duration of therapy and at least 3 months
thereafter. Azathioprine is considered low risk in pregnancy without a signifi-
cant increase inmajor congenital malformations [68, 69]. There is less guidance
available on the risk of paternal immunosuppressant exposure. The British
Association of Dermatologists’ guidelines for the use of azathioprine state that
studies do confirm male patients receiving azathioprine father healthy children
and standard dose azathioprine does not appear to affect fertility [70].
There is still little research on pregnancy outcomes in patients with
vasculitis. Two recent reports suggest that relapse during pregnancy is un-
common and that outcomes when disease is controlled prior to conception
are good [71, 72].
Thromboembolic disease
Although microthrombosis is a component of vasculitic pathology, the fre-
quency of deep venous thrombosis and pulmonary embolism is also increased,
being highest during periods of disease activity and inflammation. A rate of
15% was reported in a prospective trial; and in retrospective surveys, rates of
1.8%/year for all AAV patients rising to 6.7–9%/year for those with active
disease were reported [73]. Autoantibodies to plasminogen and tissue
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plasminogen activator occur in the sera of 25 and 14% of AAV patients [74].
Their presence has been associated with more severe renal outcomes and
increased risk for thromboembolic events. Anti-coagulants have been used
historically in the treatment of renal vasculitis, but thromboprophylactic strat-
egies have not been developed for AAV in the current era. Until further data
emerges of the clinical utility of anti-plasminogen autoantibody testing, it is
advisable to address conventional risk factors andmaintain a high threshold for
suspicion of thromboembolism.
Risk of relapse versus prolonged maintenance therapy
Relapse in AAV occurs in 30–50% of patients by 5 years, with an increased risk
associated with GPA, PR3-ANCA specificity, ear nose and throat involvement,
persisting ANCA positivity after induction therapy, a lower serum creatinine at
diagnosis and early withdrawal of corticosteroids or immunosuppressives [75].
However, prolonged duration of maintenance therapy is associated with in-
creased exposure to the toxicities of immunosuppressives and corticosteroids.
Current recommendations suggest at least 24months of induction therapy once
remission has been obtained, although, the optimal duration of remission-
maintenance therapy remains unknown [7].
The recent REMAIN trial (prolonged REmission-MAINtenance therapy in
systemic vasculitis) by EUVAS looked at whether continued azathioprine/
prednisolone was more effective in preventing relapse in AAV than their with-
drawal at 24 months. It demonstrated that continuation of corticosteroids and
azathioprine beyond 2 years reduced the relapse risk and improved renal
outcome. Continuation of immunosuppressive therapy was associated with a
trend towards more frequent adverse events such as malignancy, infections and
cardiovascular complications (p = 0.07) [76]. However, another study investi-
gating the use of prolonged azathioprine to prevent disease relapse failed to
show benefit [77].
Further research is required to identify clinical or biologicalmarkers that will
help to identify high-risk patients who require prolonged therapy, until then,
the treating clinician must weigh up the individual risk of relapse compared
with the risk of treatment toxicity.
Conclusion
Over the last 20 years, careful use and monitoring of cyclophosphamide and
corticosteroid-based treatment regimens have improved outcomes [78]. This
may be improved further with use of rituximab as an alternative to cyclophos-
phamide and new therapies reducing the need for corticosteroids.
It is the responsibility of the treating clinician to assess every patient as an
individual, considering the risks associated with AAV therapy before com-
mencement of induction therapy, using the risk factors identified for adverse
events and mortality including increasing age and declining kidney function
[3]. Individual patient risk of relapse must be balanced against risk from
treatment toxicity when deciding duration of maintenance therapy.
The impact of this chronic relapsing disease and the burden of therapy on
patients’ physical and emotional wellbeing are significant, with fatigue being a
considerable concern. Many patients experience reduced quality of life despite
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successful therapy. We must identify patient priorities at the start of treatment
with regular reassessment, alongside patient education on both the nature of
their disease and the considerable risks from disease and therapy. This will aid
clinicians and patients with shared decision-making to achieve the best out-
comes for patients with AAV.
Until the development of treatments without the significant side effects that
still remain from current regimens, we need to focus on prophylaxis to prevent
the known toxicity from AAV therapies.
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